Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
ALLO vs ARRY: Biotech Catalysts Against Solar Sector Fundamentals

ALLO vs ARRY: Biotech Catalysts Against Solar Sector Fundamentals

Key Takeaways

  • Allogene Therapeutics (ALLO) is a clinical-stage biotech advancing "off-the-shelf" allogeneic CAR T cell therapies, while Array Technologies (ARRY) is a commercial manufacturer of solar tracking systems for utility-scale projects.
  • ALLO's recent performance has been driven by positive trial data for its lead candidate, cema-cel, while ARRY has posted record order-book growth despite pressure on its share price in recent weeks.
  • The two companies carry very different risk profiles: ALLO is pre-revenue with clinical and cash-burn risk, whereas ARRY is profitable but exposed to solar industry pricing and policy uncertainty.
  • ALLO trades with a smaller market capitalization and heightened volatility typical of development-stage biotech, while ARRY trades at a comparatively low forward price-to-earnings (P/E) multiple.
  • Relative performance and market positioning diverge sharply between the two names, reflecting their distinct sectors (healthcare versus energy/industrials) and growth catalysts.
  • For deeper coverage, explore ALLO Major News and ALLO Today's Price Move, plus ARRY Major News and ARRY Today's Price Move.
  • To see how AI-driven strategies are currently navigating this market, explore Trending AI Robots.

Why Pair These Two Very Different Names

This comparison brings together two companies operating in separate corners of the market, both of which draw attention from traders looking for catalyst-driven setups. ALLO is a development-stage biotechnology firm where valuation rests heavily on clinical trial results, while ARRY is an established industrial manufacturer whose results track utility-scale solar demand. Investors focused on biotech catalysts and long-term clinical upside may find ALLO compelling, whereas those seeking revenue-generating operations and value-style metrics may gravitate toward ARRY. Comparing their relative performance and market positioning shows how distinct risk and reward profiles can coexist in the same environment.

ALLO Overview and Recent Performance

Allogene Therapeutics develops "off-the-shelf" allogeneic CAR T cell therapies — engineered immune cells derived from healthy donors rather than a patient's own cells — for cancer and autoimmune diseases. Its lead candidate, cema-cel, is being evaluated in the pivotal Phase 2 ALPHA3 trial for first-line large B-cell lymphoma (LBCL). In recent months, interim data showed a 58.3% rate of minimal residual disease (MRD) negativity at day 45 versus 16.7% for observation, with no treatment-related serious adverse events reported at the cutoff. The company has also received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA).

Sentiment has been shaped by both this clinical progress and financial discipline: ALLO ended its most recent quarter with roughly $423.6 million in cash and investments, which management expects to fund operations into 2029. Despite these advances, the stock has experienced notable volatility and a pullback in recent weeks, trading well below its 52-week high. As a pre-revenue company, ALLO's performance remains tied to data readouts, regulatory milestones, and continued cash-burn management. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ARRY Overview and Recent Performance

Array Technologies is a global manufacturer of ground-mounted solar tracking systems that help utility-scale solar panels follow the sun to maximize energy output. The company has broadened its platform through acquisitions, adding engineered foundations, cable management, and software to its offerings. In its most recent quarter, ARRY reported record order-book levels of approximately $2.5 billion, up 37% year over year, alongside a trailing 12-month book-to-bill ratio of about 1.5x, indicating strong demand for its products.

Despite this operational momentum, ARRY's share price has declined meaningfully in recent weeks, and the stock trades below levels seen earlier in the year. Investors have weighed near-term headwinds including project timing, a shift toward international mix, input costs, and policy uncertainty around tariffs. The company reaffirmed full-year revenue guidance while raising margin expectations, yet near-term revenue cadence and cash-flow conversion remain key watchpoints. ARRY's forward P/E ratio is notably lower than its industry average, reflecting the market's cautious stance toward solar-sector fundamentals.

Head-to-Head Comparison

The most fundamental contrast between these two stocks is business-model maturity. ALLO generates minimal revenue and depends on clinical validation and eventual regulatory approval, while ARRY is an operating business with hundreds of millions of dollars in quarterly revenue and a growing order book. This translates into divergent risk profiles: ALLO carries binary, event-driven risk around trial readouts, whereas ARRY faces cyclical and policy-driven risk tied to solar project economics and tariffs.

Growth drivers also differ. ALLO's upside is concentrated in cema-cel and its earlier-stage autoimmune program, where positive data could meaningfully re-rate the stock. ARRY's growth depends on book-to-bill momentum, margin expansion, and successful integration of recent acquisitions. From a sentiment standpoint, both stocks have faced recent selling pressure, but ALLO has benefited from a string of positive clinical catalysts, while ARRY's strong fundamentals have not yet translated into sustained share-price momentum. Sector exposure is another key differentiator: ALLO sits in biotechnology and is sensitive to clinical and regulatory news, whereas ARRY belongs to the solar/industrials complex and reacts to energy policy and interest-rate dynamics.

Tickeron AI Verdict

Based on observable factors such as trend consistency, stability, and catalyst quality, Tickeron's AI would likely treat these names quite differently. ARRY offers more measurable fundamentals — revenue, margins, and a record order book — but its recent price action has shown weaker trend consistency, which automated trend-following models often penalize. ALLO presents a clearer recent catalyst narrative with favorable clinical data and an extended cash runway, though its pre-revenue status and elevated volatility introduce greater instability. On balance, the AI would likely favor the name with stronger relative momentum and a more defined near-term catalyst set, while acknowledging that both stocks carry meaningful, though very different, risks. From what I see, this distinction highlights how automated systems weigh fundamentals against momentum in real time.

Exploring AI Tools for Market Analysis

One resource I frequently consult when evaluating stocks like these is Tickeron’s AI Trading Bots. The platform maintains a large library of automated strategies that trade thousands of different tickers across diverse timeframes, sectors, and risk profiles. Because not every bot is suited to every market regime, Tickeron curates only the strongest performers into its Trending AI Robots section — a focused list of the strategies currently best aligned with prevailing market conditions. These bots differ in trading style, strategy, holding period, performance metrics, and the specific sets of tickers they follow, giving traders a range of approaches to evaluate rather than a one-size-fits-all solution. I’m watching this closely because it helps surface ideas that align with current conditions without replacing individual analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARRY, ALLO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ARRY's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for ARRY moved out of overbought territory on November 09, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In 20 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARRY as a result. In 78 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for ARRY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

ARRY moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

ARRY broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ARRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for ARRY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.

Following a +40.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 191 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.462) is normal, around the industry mean (2.537). P/E Ratio (-6.099) is within average values for comparable stocks, (6.086). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ARRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.

Notable companies

The most notable companies in this group are First Solar (NASDAQ:FSLR), Enphase Energy (NASDAQ:ENPH), SolarEdge Technologies (NASDAQ:SEDG), Canadian Solar (NASDAQ:CSIQ).

Industry description

The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.

Market Cap

The average market capitalization across the Alternative Power Generation Industry is 6.02B. The market cap for tickers in the group ranges from 3.39K to 270.64B. CDVM holds the highest valuation in this group at 270.64B. The lowest valued company is MAXNQ at 3.39K.

High and low price notable news

The average weekly price growth across all stocks in the Alternative Power Generation Industry was -24%. For the same Industry, the average monthly price growth was -28%, and the average quarterly price growth was -58%. ZEO experienced the highest price growth at -1%, while SPWR experienced the biggest fall at -54%.

Volume

The average weekly volume growth across all stocks in the Alternative Power Generation Industry was 97%. For the same stocks of the Industry, the average monthly volume growth was 131% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 41
P/E Growth Rating: 44
Price Growth Rating: 76
SMR Rating: 79
Profit Risk Rating: 99
Seasonality Score: -14 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical drugs

Industry AlternativePowerGeneration

Industry
Biotechnology
Address
3901 Midway Place NE
Phone
+1 505 881-7567
Employees
1200
Web
https://www.arraytechinc.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.